Investigational Drug Details
| Drug ID: | D446 |
| Drug Name: | Darapladib |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB06311 |
| DrugBank Description: | |
| PubChem ID: | 9939609 |
| CasNo: | 356057-34-6 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CCN(CC)CCN(CC1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(=O)CN1C2=C(CCC2)C(=O)N=C1SCC1=CC=C(F)C=C1 |
| Structure: |
|
| InChiKey: | WDPFJWLDPVQCAJ-UHFFFAOYSA-N |
| Molecular Weight: | 666.78 |
| DrugBank Targets: | Cytosolic phospholipase A2 |
| DrugBank MoA: | Darapladib is a selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzymatic upstream mediator of inflammatory processes. Evidence from experimental settings show that the breakdown products from oxidized low density lipoprotein C (LDL-C)such as lysophosphatidylcholine species and oxidized nonesterified fatty acids are pro-inflammatory and pro-apoptotic. These products are suspected to cause athlerosclerosis progression and plaque vulnerability, which leads to increased risk of cardiovascular problems. |
| DrugBank Pharmacology: | |
| DrugBank Indication: | Investigated for use/treatment in atherosclerosis. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|